| Document Date: 2009-12-02 18:21:00
Open Document File Size: 251,19 KBShare Result on Facebook
City Lexington / / Company Flagship Ventures / TARIS Biomedical Inc. / Flybridge Capital Partners / Polaris Venture Partners / / Country United States / / Event FDA Phase / / Facility Massachusetts Institute of Technology / / IndustryTerm venture capital / treatment of bladder diseases / sustained-release technology / therapeutic solutions / platform technology / pharmaceutical / local minimally-invasive drug-device convergence products / / MedicalCondition bladder diseases / overactive bladder / disease / bladder disease / bladder cancer / interstitial cystitis / chronic pelvic pain syndrome / pain / diseases / bladder syndrome / urinary tract infections / / Organization MIT / David Koch Institute / Massachusetts Institute of Technology / / Person Robert Langer / Michael Cima / Christine Bunt / Robert S. Langer / Rand Interstitial Cystitis Epidemiology / / Position co-founder and COO / Professor / co-founder / / Product Lidocaine / Several Indications / / ProvinceOrState Massachusetts / / Technology drug-delivery / platform technology / sustained-release technology / / URL www.tarisbiomedical.com / /
SocialTag |
TARIS SUCCESSFULLY COMPLETES PHASE 1 STUDY -- First Human Trial Enables Development for Several Indications -Lexington, MA – December 2, 2009 – TARIS Biomedical, a specialty pharmaceutical company pioneering the fiel